Articles

Videos

Podcasts

Clinical

The treatment regimen is first in more than 20 years to significantly improve outcomes in individuals with the fast-growing cancer, according to the company.

FDA Accepts sBLA for Genentech’s Polivy Combination for Diffuse Large B-Cell Lymphoma

Kcentra is indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy in adult patients with acute major bleeding.

Daily Medication Pearl: Kcentra [Prothrombin Complex Concentrate (Human)]

For pediatric patients with B-cell acute lymphoblastic leukemia, higher doses of tisagenlecleucel increased their rate of survival after 1 year by nearly 30%.

High Dose of Tisagenlecleucel Linked to Better Survival Rate for B-Cell Acute Lymphoblastic Leukemia

Zynteglo was approved for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions after safety and efficacy were demonstrated in clinical trials.

FDA Approves Zynteglo for Patients with Beta-thalassemia Requiring Regular Blood Transfusions

Zoledronic acid (Zometa) is indicated for the treatment of hypercalcemia that may occur with cancer.

Daily Medication Pearl: Zoledronic Acid (Zometa)

Both ibrutinib (Imbruvica) and venetoclax (Venclexta) carry an approved indication for use in chronic lymphocytic leukemia but do not often lead to complete remission, and therapy routinely continues indefinitely or until disease progression. 

Oncology Overview: Treatment of Chronic Lymphocytic Leukemia with Ibrutinib, Venetoclax

With costs for blood and blood products continuing to rise, appropriate blood use by hospitals is more important than ever.

Op-Ed: Unnecessary Transfusions in Hospitals May Be Fueling the Blood Shortage

A potential public health benefit of 13-valent pneumococcal conjugate vaccine is the reduction of acute chest syndrome among children with sickle-cell disease.

PCV13 Vaccination May Reduce Incidence of Acute Chest Syndrome for Children with Sickle-Cell Disease

Humate-P is indicated for the treatment of adult patients with classical hemophilia (hemophilia A) and von Willebrand disease (VWD).

Daily Medication Pearl: Humate-P

The company-sponsored phase 1/2 study evaluates a cryopreserved, readily available formulation for the treatment of follicular and diffuse large B cell lymphomas.

Gamida Cell Announces Dosing of First Patient for NK Cell Therapy Candidate GDA-201

® Hematology Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of blood disorders, include blood and bone marrow cancers, anemia, hemophilia, blood-clotting disorders, and leukemia.